Compare ADVM & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADVM | XTNT |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 82.6M |
| IPO Year | 2014 | N/A |
| Metric | ADVM | XTNT |
|---|---|---|
| Price | $4.36 | $0.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $11.60 | $1.50 |
| AVG Volume (30 Days) | ★ 497.5K | 160.7K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $133,083,000.00 |
| Revenue This Year | $1,192.00 | $15.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $64.86 |
| Revenue Growth | N/A | ★ 16.88 |
| 52 Week Low | $1.78 | $0.33 |
| 52 Week High | $6.12 | $0.95 |
| Indicator | ADVM | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 57.00 |
| Support Level | $4.15 | $0.68 |
| Resistance Level | $4.23 | $0.78 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 95.22 | 64.76 |
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.